Endocrinol Metab.  2021 Feb;36(1):51-56. 10.3803/EnM.2021.108.

Best Achievements in Pituitary and Adrenal Diseases in 2020

Affiliations
  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
  • 2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
  • 3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
  • 4Pituitary Center, Seoul National University Hospital, Seoul, Korea

Abstract

Significant progress in pituitary and adrenal diseases was made in 2020. This review presents major translational and clinical advances in research on pituitary and adrenal diseases, encompassing their epidemiology, pathogenesis, diagnosis, and clinical management. We address the controversy regarding the nomenclature of pituitary neuroendocrine tumors, omics-based molecular classification of pituitary adenomas, and novel drugs for Cushing’s disease in the field of pituitary diseases. In the field of adrenal diseases, we cover big data-driven epidemiology of adrenal tumors, steroid profiling as a new diagnostic tool, and the utility of scoring systems in the decision-making process of managing primary aldosteronism. This brief article will broaden readers’ understanding of pituitary and adrenal diseases.

Keyword

Pituitary neoplasms; Adrenal gland neoplasms; Steroids; Big data; Decision making

Reference

1. Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017; 24:C5–8.
Article
2. Ho KK, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, et al. The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. Pituitary. 2020; 23:476–7.
Article
3. Ho KK, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, et al. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement. Pituitary. 2019; 22:569–73.
4. Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson ML, Septier A, et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell. 2020; 37:123–34.
Article
5. Abboud D, Daly AF, Dupuis N, Bahri MA, Inoue A, Chevigne A, et al. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of GS and Gq/11. Nat Commun. 2020; 11:4752.
Article
6. Li C, Xie W, Rosenblum JS, Zhou J, Guo J, Miao Y, et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun. 2020; 11:2506.
Article
7. Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019; 7:855–65.
Article
8. Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020; 8:748–61.
Article
9. Lee JM, Kim MK, Ko SH, Koh JM, Kim BY, Kim SW, et al. Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul). 2017; 32:200–18.
Article
10. Ebbehoj A, Li D, Kaur RJ, Zhang C, Singh S, Li T, et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 2020; 8:894–902.
Article
11. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020; 173:10–20.
12. Ahn CH, Kim JH, Park MY, Kim SW. Epidemiology and comorbidity of adrenal Cushing’s syndrome: a nationwide cohort study. J Clin Endocrinol Metab. 2020. Oct. 19. [Epub]. https://doi.org/10.1210/clinem/dgaa752 .
Article
13. Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020; 8:773–81.
14. Constantinescu G, Langton K, Conrad C, Amar L, Assie G, Gimenez-Roqueplo AP, et al. Glucocorticoid excess in patients with pheochromocytoma compared with paraganglioma and other forms of hypertension. J Clin Endocrinol Metab. 2020; 105:e3374–83.
Article
15. Burrello J, Burrello A, Pieroni J, Sconfienza E, Forestiero V, Rabbia P, et al. Development and validation of prediction models for subtype diagnosis of patients with primary aldosteronism. J Clin Endocrinol Metab. 2020; 105:dgaa379.
Article
16. Burrello J, Burrello A, Pieroni J, Sconfienza E, Forestiero V, Amongero M, et al. Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. Eur J Endocrinol. 2020; 183:657–67.
Article
17. Morisaki M, Kurihara I, Itoh H, Naruse M, Takeda Y, Katabami T, et al. Predictors of clinical success after surgery for primary aldosteronism in the Japanese nationwide cohort. J Endocr Soc. 2019; 3:2012–22.
Article
18. Williams TA, Lenders JW, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017; 5:689–99.
Article
19. Burrello J, Burrello A, Stowasser M, Nishikawa T, Quinkler M, Prejbisz A, et al. The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann Surg. 2020; 272:1125–32.
Article
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr